Sign In
Buy KNBIF
$0.0202
+0 (+0%)
At Close: Jul 31, 2026
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
04:30pm, Thursday, 22'nd Aug 2024
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on Thu
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
08:30am, Thursday, 22'nd Aug 2024
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
08:30am, Tuesday, 13'th Aug 2024
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services
Kane Biotech Announces Issuance of Restricted Share Units
08:30am, Monday, 15'th Jul 2024
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted sha
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
08:30am, Thursday, 11'th Jul 2024
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with Ari
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
08:30am, Thursday, 27'th Jun 2024
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyv
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
08:30am, Tuesday, 25'th Jun 2024
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement wi
Kane Biotech Announces First Quarter 2024 Financial Results
04:15pm, Thursday, 23'rd May 2024
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results.
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
08:00am, Thursday, 16'th May 2024
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
08:00am, Wednesday, 15'th May 2024
Named in Honour of the late Dr. Greg Schultz, Former Professor Emeritus at the University of Florida and Chief Science Officer of Kane Biotech Named in Honour of the late Dr. Greg Schultz, Former Prof
Kane Biotech to Host Investor Webinar
09:15am, Tuesday, 16'th Apr 2024
What the sale of STEM Animal Health means for Kane going forward – Thursday April 18th, 2024 at 4:15pm Eastern Time What the sale of STEM Animal Health means for Kane going forward – Thursday Apri
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
09:15am, Monday, 15'th Apr 2024
An important step in Kane becoming a market leader in the growing high-value wound care and dermatological markets An important step in Kane becoming a market leader in the growing high-value wound ca
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
09:45am, Thursday, 11'th Apr 2024
WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in princip
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Tuesday, 26'th Mar 2024
WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 finan
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
08:30am, Wednesday, 20'th Mar 2024
WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity perio
